CTRI/2022/09/045258
招募中
2 期
Ga68-PSMA PETCT and MR guided Boost for intra-prostatic dose Escalation - PROBE
Varian Medical System0 个研究点目标入组 0 人待定
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: C61- Malignant neoplasm of prostate
- 发起方
- Varian Medical System
- 状态
- 招募中
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1 Histological diagnosis of adenocarcinoma prostate
- •2 Suitableand planned for stereotactic body radiotherapy (SBRT) to the prostate
- •3 Visible DIL in both mpMRI and Ga68\-PSMA PETCT scans done not more than four weeks apart
排除标准
- •1 More than four weeks of androgen deprivation therapy or cancer\-directed systemic therapy before baseline imaging
- •2 Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist
- •3 IPSS \>20
- •4 Prior TURP within 3 months
- •5 Urethral stricture
- •6 Prostate gland volume \>80cc
- •7 cT4 (AJCC 8th)
- •8 Untreated anal hemorrhoids/fissures
- •9 Pt unable to consent
- •10 Patients unwilling or unreliable for regular follow\-up and surveillance imaging
结局指标
主要结局
未指定
相似试验
已完成
不适用
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinomaNL-OMON44299Radboud Universitair Medisch Centrum25
进行中（未招募）
1 期
PSMA-PET scan for incurable or metastatic salivary gland cancerEUCTR2017-002093-40-NLRadboudumc25
Unknown
2 期
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate CancerProstate CancerNCT02282137Ebrahim Delpassand208
进行中（未招募）
1 期
Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validatioEUCTR2015-005046-55-SEmeå University Hospital
Unknown
不适用
Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3Prostatic NeoplasmsNCT04573179The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School60